Siemens Healthineers AG announces its results for the third quarter of fiscal year 2025 ended June 30, 2025.
Q3 Fiscal Year 2025
- Good equipment book-to-bill ratio of 1.09
- Very strong comparable revenue growth of 7.6%
- Imaging shows excellent comparable revenue growth of 11.7%; adjusted EBIT margin 21.0%
- Diagnostics posts slight comparable revenue decline of 0.6%; adjusted EBIT margin 9.2%
- Varian comparable revenue growth 8.7%; adjusted EBIT margin 18.8%
- Advanced Therapies comparable revenue growth 4.5%; adjusted EBIT margin 10.5%
- Overall adjusted EBIT margin 16.8%, clearly above prior-year quarter
- Free cash flow up by more than 50% from prior-year quarter to around €840 million
- Adjusted basic earnings per share €0.64, clearly above prior-year quarter
Updated Outlook for Fiscal Year 2025
As a result of the latest geopolitical developments, in particular the agreements on trade tariffs, we narrow the ranges for comparable revenue growth and adjusted basic earnings per share in our outlook for fiscal year 2025. We also raise the midpoints of the ranges, mainly due to our performance year to date. We now expect comparable revenue growth of between 5.5% and 6% over fiscal year 2024 (previously between 5% and 6%) and adjusted basic earnings per share of between €2.30 and €2.45 (previously between €2.20 and €2.50).
Bernd Montag, CEO of Siemens Healthineers AG:
”We had a very good quarter with high revenue growth, another increase in profitability and strong free cash flow. Therefore we are raising the midpoints of our outlook. While volatility in the geopolitical environment remains high, our performance shows the value of our healthcare innovations for more and more patients around the world.”
Source & Image Credit: Siemens Healthineer
